English
Home > Products > Temozolomide intermediate

China Temozolomide intermediate Factory

"Sincerity, Innovation, Rigorousness, and Efficiency" is the persistent conception of our firm for the long-term to create jointly with consumers for mutual reciprocity and mutual reward for Temozolomide intermediate,CAS NO 360-97-4,360-97-4,Dacarbazine intermediate,Dacarbazine advance intermediate, Being a young escalating company, we might not the top, but we're trying our best to generally be your superior partner.
Temozolomide intermediate, We'll supply much better products and solutions with diversified designs and expert services. At the same time, welcome OEM, ODM orders, invite friends at home and abroad together common development and achieve win-win, integrity innovation, and expand business opportunities! If you have any question or need more information be sure to feel free to contact us. We are looking forward to receiving your enquiries soon.

Related Products

Hot Products

  • Related Blog
  • Reviews

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications.

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • How much do you know about minocycline hydrochloride?

    Minocycline hydrochloride is commonly used as its hydrochloride, which is yellow crystalline powder, odorless, bitter in taste, and can cause deterioration when exposed to light. Soluble in water, slightly soluble in ethanol, easily soluble in alkali metal hydroxide or carbonate solution.

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept